CATALYST PHARMACEUTICALS INC (CPRX)
US14888U1016 - Common Stock
We assign a fundamental rating of 8 out of 10 to CPRX. CPRX was compared to 565 industry peers in the Biotechnology industry. CPRX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. CPRX is growing strongly while it also seems undervalued. This is an interesting combination These ratings would make CPRX suitable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year CPRX was profitable.
In the past year CPRX had a positive cash flow from operations.
CPRX had positive earnings in each of the past 5 years.
In the past 5 years CPRX always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 9.64%, CPRX belongs to the top of the industry, outperforming 96.08% of the companies in the same industry.
The Return On Equity of CPRX (11.19%) is better than 95.72% of its industry peers.
With an excellent Return On Invested Capital value of 10.83%, CPRX belongs to the best of the industry, outperforming 95.72% of the companies in the same industry.
CPRX had an Average Return On Invested Capital over the past 3 years of 20.38%. This is significantly above the industry average of 15.31%.
The last Return On Invested Capital (10.83%) for CPRX is well below the 3 year average (20.38%), which needs to be investigated, but indicates that CPRX had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.64% | ||
| ROE | 11.19% | ||
| ROIC | 10.83% |
ROA(3y)17.98%
ROA(5y)24.26%
ROE(3y)21.72%
ROE(5y)29.16%
ROIC(3y)20.38%
ROIC(5y)21.58%
1.3 Margins
CPRX has a Profit Margin of 15.68%. This is amongst the best in the industry. CPRX outperforms 96.08% of its industry peers.
In the last couple of years the Profit Margin of CPRX has declined.
CPRX has a better Operating Margin (19.76%) than 96.08% of its industry peers.
In the last couple of years the Operating Margin of CPRX has declined.
CPRX has a better Gross Margin (86.67%) than 90.02% of its industry peers.
In the last couple of years the Gross Margin of CPRX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.76% | ||
| PM (TTM) | 15.68% | ||
| GM | 86.67% |
OM growth 3Y-14.33%
OM growth 5YN/A
PM growth 3Y-34.21%
PM growth 5YN/A
GM growth 3Y0.51%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CPRX is creating value.
The number of shares outstanding for CPRX has been increased compared to 1 year ago.
CPRX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CPRX has an Altman-Z score of 17.52. This indicates that CPRX is financially healthy and has little risk of bankruptcy at the moment.
CPRX has a better Altman-Z score (17.52) than 91.62% of its industry peers.
There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 17.52 |
ROIC/WACC1.04
WACC10.41%
2.3 Liquidity
CPRX has a Current Ratio of 5.14. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.14, CPRX is in line with its industry, outperforming 55.79% of the companies in the same industry.
CPRX has a Quick Ratio of 4.94. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
CPRX's Quick ratio of 4.94 is in line compared to the rest of the industry. CPRX outperforms 55.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.14 | ||
| Quick Ratio | 4.94 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 63.89% over the past year.
Measured over the past years, CPRX shows a very strong growth in Earnings Per Share. The EPS has been growing by 25.48% on average per year.
The Revenue has grown by 85.90% in the past year. This is a very strong growth!
The Revenue has been growing by 280.39% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)63.89%
EPS 3Y25.48%
EPS 5YN/A
EPS Q2Q%220.69%
Revenue 1Y (TTM)85.9%
Revenue growth 3Y49.53%
Revenue growth 5Y280.39%
Sales Q2Q%25.33%
3.2 Future
The Earnings Per Share is expected to grow by 27.45% on average over the next years. This is a very strong growth
Based on estimates for the next years, CPRX will show a quite strong growth in Revenue. The Revenue will grow by 11.42% on average per year.
EPS Next Y46.07%
EPS Next 2Y37.44%
EPS Next 3Y31.92%
EPS Next 5Y27.45%
Revenue Next Year21.03%
Revenue Next 2Y19.48%
Revenue Next 3Y18.06%
Revenue Next 5Y11.42%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
CPRX is valuated rather expensively with a Price/Earnings ratio of 17.90.
Compared to the rest of the industry, the Price/Earnings ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 96.08% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 28.96, CPRX is valued a bit cheaper.
With a Price/Forward Earnings ratio of 13.80, CPRX is valued correctly.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 96.26% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.82. CPRX is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.9 | ||
| Fwd PE | 13.8 |
4.2 Price Multiples
95.72% of the companies in the same industry are more expensive than CPRX, based on the Enterprise Value to EBITDA ratio.
98.04% of the companies in the same industry are more expensive than CPRX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.82 | ||
| EV/EBITDA | 17.54 |
4.3 Compensation for Growth
CPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CPRX has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as CPRX's earnings are expected to grow with 31.92% in the coming years.
PEG (NY)0.39
PEG (5Y)N/A
EPS Next 2Y37.44%
EPS Next 3Y31.92%
5. Dividend
5.1 Amount
No dividends for CPRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CATALYST PHARMACEUTICALS INC
NASDAQ:CPRX (11/21/2024, 5:20:01 PM)
After market: 21.12 0 (0%)21.12
-0.03 (-0.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.52B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.9 | ||
| Fwd PE | 13.8 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.39
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.64% | ||
| ROE | 11.19% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 19.76% | ||
| PM (TTM) | 15.68% | ||
| GM | 86.67% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.14 | ||
| Quick Ratio | 4.94 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)63.89%
EPS 3Y25.48%
EPS 5Y
EPS Q2Q%
EPS Next Y46.07%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)85.9%
Revenue growth 3Y49.53%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y